Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Heide L Ford

Showing results (71-80 of 85) with videos related to

Pageof 9
Sort By:
Cell Reports|February 2, 2022
SIX1 reprograms myogenic transcription factors to maintain the rhabdomyosarcoma undifferentiated stateJessica Y Hsu, Etienne P Danis, Stephanie Nance, et al.
Protein Science : a Publication of the Protein Society|November 11, 2021
Structure-activity relationship studies of allosteric inhibitors of EYA2 tyrosine phosphataseJothi Anantharajan, Nithya Baburajendran, Grace Lin, et al.
Biorxiv : the Preprint Server for Biology|June 12, 2025
eIF3d and eIF3e mediate selective translational control of hypoxia that can be inhibited by novel small moleculesStephen C Purdy, Kate Matlin, Christopher Alderman, et al.
Nature Communications|December 22, 2015
The Six1 oncoprotein downregulates p53 via concomitant regulation of RPL26 and microRNA-27a-3pChristina G Towers, Anna L Guarnieri, Doug S Micalizzi, et al.
Cell Reports|December 9, 2025
eIF3d and eIF3e mediate selective translational control of hypoxia that can be inhibited by small moleculesStephen C Purdy, Kate Matlin, Christopher Alderman, et al.
The Journal of Biological Chemistry|April 24, 2014
Allosteric inhibitors of the Eya2 phosphatase are selective and inhibit Eya2-mediated cell migrationAaron B Krueger, David J Drasin, Wendy A Lea, et al.
JCI Insight|April 14, 2022
Sine oculis homeobox homolog 1 plays a critical role in pulmonary fibrosisCory Wilson, Tinne Cj Mertens, Pooja Shivshankar, et al.
Cell Reports|January 23, 2026
Retinal determination network reactivation drives chemoresistance and blocks myeloid differentiation in acute myeloid leukemiaLiam Clayfield, Divya Malik, Jessica Whittle, et al.
Neuro-Oncology|July 24, 2023
EYA2 tyrosine phosphatase inhibition reduces MYC and prevents medulloblastoma progressionArthur R Wolin, Melanie Y Vincent, Taylor Hotz, et al.
Molecular Cancer Therapeutics|July 10, 2019
Structural and Functional Analyses of an Allosteric EYA2 Phosphatase Inhibitor That Has On-Target Effects in Human Lung Cancer CellsJothi Anantharajan, Hengbo Zhou, Lingdi Zhang, et al.
Pageof 9

Showing results (71-80 of 85) with videos related to

Sort By:
Pageof 9
Cell Reports|February 2, 2022
SIX1 reprograms myogenic transcription factors to maintain the rhabdomyosarcoma undifferentiated stateJessica Y Hsu, Etienne P Danis, Stephanie Nance, et al.
Protein Science : a Publication of the Protein Society|November 11, 2021
Structure-activity relationship studies of allosteric inhibitors of EYA2 tyrosine phosphataseJothi Anantharajan, Nithya Baburajendran, Grace Lin, et al.
Biorxiv : the Preprint Server for Biology|June 12, 2025
eIF3d and eIF3e mediate selective translational control of hypoxia that can be inhibited by novel small moleculesStephen C Purdy, Kate Matlin, Christopher Alderman, et al.
Nature Communications|December 22, 2015
The Six1 oncoprotein downregulates p53 via concomitant regulation of RPL26 and microRNA-27a-3pChristina G Towers, Anna L Guarnieri, Doug S Micalizzi, et al.
Cell Reports|December 9, 2025
eIF3d and eIF3e mediate selective translational control of hypoxia that can be inhibited by small moleculesStephen C Purdy, Kate Matlin, Christopher Alderman, et al.
The Journal of Biological Chemistry|April 24, 2014
Allosteric inhibitors of the Eya2 phosphatase are selective and inhibit Eya2-mediated cell migrationAaron B Krueger, David J Drasin, Wendy A Lea, et al.
JCI Insight|April 14, 2022
Sine oculis homeobox homolog 1 plays a critical role in pulmonary fibrosisCory Wilson, Tinne Cj Mertens, Pooja Shivshankar, et al.
Cell Reports|January 23, 2026
Retinal determination network reactivation drives chemoresistance and blocks myeloid differentiation in acute myeloid leukemiaLiam Clayfield, Divya Malik, Jessica Whittle, et al.
Neuro-Oncology|July 24, 2023
EYA2 tyrosine phosphatase inhibition reduces MYC and prevents medulloblastoma progressionArthur R Wolin, Melanie Y Vincent, Taylor Hotz, et al.
Molecular Cancer Therapeutics|July 10, 2019
Structural and Functional Analyses of an Allosteric EYA2 Phosphatase Inhibitor That Has On-Target Effects in Human Lung Cancer CellsJothi Anantharajan, Hengbo Zhou, Lingdi Zhang, et al.
Pageof 9